Fresenius Medical Care AG (FMS) Looks to Improve Profitability After Smashing Q4 Expectations

Core Insights - Fresenius Medical Care AG (NYSE:FMS) is recognized as one of the top German stocks to buy, with a strong performance in Q4 2025 [1] - The company reported an EPS of €1.14 for Q4 2025, a significant increase from €0.23 in Q4 2024, while revenue remained flat at €5.1 billion [1][3] Financial Performance - The management indicated that the earnings met internal targets, attributing success to a three-year focus on building resilience and disciplined operational and financial decisions [3] - A proposed dividend of €1.49 per share for 2025 earnings represents a 3% increase, with a payout ratio of approximately 33% [5] Future Outlook - Fresenius Medical Care AG aims to enhance profitability and plans to invest in future growth while addressing regulatory challenges [4] - The company projects a compound annual growth rate (CAGR) of 3% to 7% for operating income from 2025 to 2028 [4] Company Operations - Fresenius Medical Care AG operates a network of 3,601 kidney dialysis clinics, serving around 292,000 patients globally, and also manufactures dialysis machines [6]